What is Synjardy (5 mg) and what is it used for?
Synjardy is a prescription medicine for type 2 diabetes. It contains two active ingredients: empagliflozin and metformin. Depending on the exact product strength, the “5 mg” label refers to the empagliflozin dose (the metformin dose is specified separately on the same product). Empagliflozin helps lower blood sugar by increasing glucose excretion in the urine, while metformin lowers glucose by reducing liver glucose production and improving insulin sensitivity.
Synjardy is used to help control blood sugar in adults with type 2 diabetes, typically as part of a regimen that also includes diet and exercise.
What does “Synjardy 5 mg” mean exactly?
“5 mg” in Synjardy product naming points to the empagliflozin component strength. Synjardy products combine empagliflozin with metformin, and the metformin amount may differ by formulation (for example, immediate-release vs extended-release) even when the empagliflozin dose is 5 mg. To be sure you have the right medicine, check the full label for both ingredients and their doses.
How is Synjardy usually taken?
Dosing depends on the specific Synjardy formulation and your starting regimen. In general, metformin-containing diabetes medicines are started at a dose meant to reduce stomach side effects, and dosing may be adjusted based on blood sugar control and kidney function.
Because empagliflozin-containing drugs require kidney-dose considerations, your prescriber will base dosing on your renal function.
What are common side effects patients ask about?
Patients commonly report side effects that fit the known effects of each component:
- Metformin-related gastrointestinal issues such as nausea, diarrhea, abdominal discomfort, or loss of appetite.
- Empagliflozin-related risks including genital fungal infections and increased urination.
Some patients also ask about symptoms that could signal dehydration or a serious infection, which require prompt medical attention.
What safety concerns matter most with empagliflozin + metformin?
Key risk areas include:
- Genital infections (more likely with SGLT2 inhibitors like empagliflozin).
- Dehydration or low blood pressure risk, especially in people who are older, volume depleted, or taking certain blood pressure diuretics.
- Kidney-related dosing limits, since empagliflozin use depends on kidney function.
- Serious metabolic complications are rare but important with diabetes medicines overall; seek urgent care for severe symptoms (such as rapid breathing, unusual fatigue, or persistent vomiting) as directed by the prescribing clinician.
Who shouldn’t take Synjardy (or needs extra monitoring)?
You may need to avoid Synjardy or use it only with careful monitoring if you have:
- Significant kidney impairment.
- A history of certain metabolic problems tied to metformin risk (your clinician will screen for this).
- Conditions that raise the risk of dehydration or low blood pressure.
Your prescriber should also review your other medicines to reduce the risk of drug interactions and overlapping side effects.
How does Synjardy compare to taking empagliflozin and metformin separately?
Synjardy simply combines empagliflozin and metformin into one product, which can make adherence easier than taking separate pills. The clinical effect is driven by the same two active ingredients, so switching between a combination product and separate prescriptions generally follows the same dosing logic (empagliflozin 5 mg plus the specific metformin dose).
Pricing and patent/exclusivity checks
If you are researching commercial availability, competitors, or patent status for Synjardy (including the empagliflozin-metformin combinations), DrugPatentWatch.com is a useful reference point for patent/exclusivity tracking.
Source: DrugPatentWatch.com
Quick check: how to make sure you have the right Synjardy product
Because “5 mg” can refer specifically to empagliflozin within a multi-component tablet, confirm on the package label:
- Empagliflozin dose (the “5 mg” part)
- Metformin dose and whether it’s immediate-release or extended-release (wording on the label will indicate this)
If you share the exact label text (for example, the full strength listing and whether it says XR/extended-release), I can help interpret what “5 mg” corresponds to and what that specific strength is typically used for.
Sources cited:
1. https://www.drugpatentwatch.com/p/synjardy/